COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE (1L) SYSTEMIC TREATMENTS IN ADVANCED RENAL CELL CARCINOMA (ARCC) IN FRANCE

被引：0
|
作者：
Tempelaar, S. [1 ]
Kroep, S. [1 ]
Marie, L. [2 ]
Juban, L. [2 ]
Kurt, M. [3 ]
Ejzykowicz, F.
May, J. R. [4 ]
Gaudin, A. F. [5 ]
Dhanji, N. [6 ]
Branchoux, S. [5 ]
机构：
[1] OPEN Hlth, Rotterdam, Netherlands
[2] Steve Consultants, Paris, France
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Bristol Myers Squibb, Uxbridge, Middx, England
[5] Bristol Myers Squibb, Rueil Malmaison, France
[6] OPEN Hlth, Oxford, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA150
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of first-line treatments in metastatic renal cell carcinoma
    Benton, John Z.
    Klaassen, Zachary
    Wallis, Christopher J. D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (02) : 285 - 286
  • [2] Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC)
    Naqvi, Syed Arsalan Ahmed
    Faisal, Kunwer Sufyan
    Raina, Ammad
    Khakwani, Kaneez Zahra Rubab
    Bin Riaz, Zaryab
    Shah, Vishal S.
    Cobran, Ewan Kemar
    Singh, Parminder
    Hussain, Syed A.
    Bryce, Alan Haruo
    Bin Riaz, Irbaz
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I/P) prognostic risk
    Choueiri, T. K.
    Stwalley, B.
    Huo, S.
    May, J. R.
    Malcolm, B.
    Nickel, K.
    Szabo, N.
    Klijn, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S563 - S564
  • [4] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [5] MULTIDIMENSIONAL TREATMENT EFFECT NETWORK META-ANALYSIS TO ESTIMATE SURVIVAL OF THERAPIES FOR PATIENTS WITH FIRST-LINE (1L) ADVANCED OR METASTATIC RENAL CELL CARCINOMA (ARCC) IN FRANCE
    Gittfried, A. M., V
    Lambton, M.
    Nickel, K.
    May, J. R.
    Branchoux, S.
    Kroep, S.
    VALUE IN HEALTH, 2022, 25 (01) : S25 - S25
  • [6] Economic implications of the first-line treatment of advanced renal cell carcinoma in Thailand: A cost-effectiveness analysis
    Topibulpong, N.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Vinayanuwattikun, C.
    Sriuranpong, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] ECONOMIC IMPLICATIONS OF THE FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THAILAND: A COST-EFFECTIVENESS ANALYSIS
    Topibulpong, N.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Vinayanuwattikun, C.
    Sriuranpong, V
    VALUE IN HEALTH, 2010, 13 (07) : A513 - A513
  • [8] Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.
    Gajra, Ajeet
    Jeune-Smith, Yolaine
    Vaishampayan, Ulka N.
    Rupard, Skyler
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).
    Mantia, Charlene
    Jegede, Opeyemi
    Regan, Meredith M.
    Atkins, Michael B.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era.
    Parikh, Divya Ahuja
    Serrato, Paul Irvin
    Srinivas, Sandy
    Ryckman, Tess Sophie
    Salomon, Joshua
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345